Determining the efficacy of novel anti-androgens in models of castrate resistant prostate cancer
Currently, androgen ablation therapy for advanced prostate cancer (PCa) attempts to inactivate the androgen receptor (AR) by diminishing circulating androgen levels and/or inhibiting AR ligand-binding. Although patient response is initially positive, the cancer ultimately recurs in a more aggressive...
Main Author: | O'Neill, Daniel James |
---|---|
Published: |
University of Newcastle upon Tyne
2014
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.720010 |
Similar Items
-
Characterising novel phosphatase enzymes important in regulating androgen receptor function in the progression of castrate resistant prostate cancer
by: Grey, James Cameron
Published: (2017) -
Identifying mechanisms of androgen receptor variant regulation in models of castrate resistant prostate cancer
by: Jones, Dominic Louis
Published: (2016) -
FABP5-related signalling pathway used as therapeutic target for castration-resistance prostate cancer
by: Al-Jameel, W. H.
Published: (2017) -
The radiation targeting of PTEN-deficiency in castration-resistant prostate cancer in combination with modulators of DNA damage repair
by: Hanna, Conor J.
Published: (2015) -
The role of MAF, an androgen regulated transcription factor in prostate cancer
by: O'Hanlon Brown, Ciara
Published: (2012)